Introduction
The introduction of genes into cells has become an effective method for the expression of proteins, both for experimental manipulation and for therapeutic purposes. One model for manipulating cochlear functions in vivo relies upon transgenic mouse technologies, that allows for the over-expression or 'knock-out' of gene constructs potentially critical to cochlea hair cell function. Several problems with traditional transgenic mouse techniques include the expense and time involved in isolating the transgenic lines of mice. In addition, due to the small size of the mouse cochlea, isolated hair cell experiments are exceedingly difficult. Finally, the mouse strain most commonly used for the initial recombination events in embryonic stem cells, the 129SvEv strain, is extremely resistant to noise-damage, 1 and thus is not an ideal model system in which to elucidate all aspects of cochlear function.
Transgenic studies in mice using bacterial artificial chromosomes (BACs) containing cochlear-specific promoters have directed transgene expression to cochlear hair cells. 2 However, these transgenes are necessarily expressed throughout development. Thus, it is not clear if the phenotype exhibited is due specifically to the somatic transgene expression, or if it is a consequence of previously altered cochlear development.
Gene delivery to the nervous system, on the other hand, offers a potential alternative to traditional transgenic approaches, and has been extensively studied, primarily using viral vectors. Of the numerous viral vectors tested, only adenoviral vector-mediated gene transfer to cochlear hair cells has been effective in vitro, as herpes simplex virus (HSV) and adeno-associated virus (AAV) failed to infect cultured hair cells.
3-6 HSV, vaccina virus, lentivirus, and AAV vectors have also failed to infect cochlear hair cells when tested in vivo. [7] [8] [9] Interestingly, replication-deficient adenoviral vectors (ie E1 − , E3 − ), using the Rous sarcoma virus (RSV) promoter to drive LacZ expression, have failed to transduce cochlear hair cells in vivo when approximately 10 7 plaque-forming units of virus were injected into scala tympani. 10 In addition, the studies using adenoviral constructs to infect cochlea cells in vivo, either did not assess cochlea function, or used a functional test (ie auditory brainstem response or ABR) that evaluated principally the ascending auditory system at the auditory nerve and brainstem level, thus, only grossly examined hair cell function.
In contrast, replication-deficient (E1
− ) adenovirus vectors, when used at higher titers (Ͼ10 8 p.f.u. per cochlea) with the CMV promoter driving green fluorescent protein expression (GFP), have been demonstrated to effectively transduce cochlear hair cells. Unfortunately, the latter is achieved at a high price, with a complete loss of outer hair cell function presumably due to the toxic nature of this class of vector. 11 The present study was designed to determine if a recently described class of modified adenovirus (E1 − , E3 − , pol − ) vector could be used to efficiently deliver genes to the cochlea in vivo, without sacrificing cochlear function. This class of vector is advantageous in that it has a demonstrated improved persistence and decreased toxicity in murine models of hepatic gene transfer. 12, 13 Since cochlear outer hair cells are more sensitive than inner hair cells to most of the common factors that impair hearing (eg excessive sounds, drug ototoxicity, bacterial or viral diseases, genetic defects, aging, etc), DPOAE testing, which primarily assesses outer hair cell function, was used to evaluate the effects of (E1
− ) transduction on peripheral cochlear function. It was anticipated that the outcome of these experiments would set the course for future interventions using gene therapy to prevent permanent deafness.
Results
In this current study, the primary aim was to determine whether the use of an improved adenovirus vector would be capable of efficiently transducing cochlear hair cells in vivo, while preserving cochlear function. One of the principal findings of an earlier study was that an (E1 − , E3 − ) adenovirus-based vector, when slowly infused into the scala tympani of the cochlea, was found to be capable of efficiently transducing cochlear hair cells in vivo, but also resulted in severely compromised cochlear function. 11 To ensure that there were no deleterious effects on cochlear function due to the implantation of the perfusion pump, or the perfusion of substances into the cochlea, three animals were chronically infused with artificial perilymph for 8 days. These control experiments demonstrated that there was no change in cochlear function as assessed using DPOAE measures in the form of the DPgram, and shown here for a representative control guinea pig subject in Figure 1b . Here, the pre-(closed circles) and post-perfusion (open circles) status of outer hair cell function, as measured with the DP-gram, are compared. From these data it can be seen that following perfusion cochlear function was unchanged, with the 8-day postperfusion DP-gram being similar to the baseline DPgram values. Figure 2a demonstrates the effect that perfusion of the replication-deficient (E1
− ) adenovirus encoding ␤-gal had on DPOAE levels for three guinea pigs. When this virus was perfused into the left ear using titers of 5 × 10 8 ␤-gal-forming units (b.f.u.)/cochlea, the DPOAEs were reduced, in that by 8 days after virus infection (open symbols), there were no detectable emissions remaining, confirming our previous results with the GFP reporter adenovirus vector. 11 In these ears there were no signs of local inflammatory responses or acute otitis media infections. In contrast, the non-perfused contralateral ears showed no reductions in DPOAE levels as shown in Figure 2b , suggesting that the vector-induced loss of cochlear function was a locally mediated response directed only to the perfused ear.
In contrast, when a modified (E1 To ascertain that the modified (E1
adenovirus actually transduced cochlear hair cells, immunohistochemistry using an antibody directed to ␤-gal was performed on both cochleae from animals that received the modified adenovirus. These results showed that the transgene (LacZ) was detected in inner hair cells and outer hair cells as shown in Figure 3e and f from a crosssection of the cochlear whole-mount shown in Figure 3c . As the functional integrity of outer hair cells was assessed using DPOAEs, the focal plane for the whole-mount photomicrographs of Figure 3a ␤-gal protein. Figure 3b shows the equivalent frequency region in the contralateral cochlea demonstrating no detectable ␤-gal present in these outer hair cells 8 days after viral infection.
The mid-to high-frequency regions of the cochleae showed even greater outer hair cell transduction using the modified adenovirus as shown by the micrographs of Figure 3c fied adenovirus. This increase in expression in the basal cochlear turns is not surprising as the virus was slowly infused into the scala tympani adjacent to the most basal turn of the cochlea. Brownian motion and the flow of perilymph from a basal to apical course through the cochlea 14 could have contributed to the virus vector diffusion. Similar to the results shown in Figure 3b with an apical turn from the contralateral cochlea, there was no transgene expression detected in hair cells of the basal turn of the corresponding contralateral cochlea as shown in Figure 3d . The percentage of hair cells transduced divided by the total hair cells present are shown in Table 1 for both basal (high frequencies) and apical (low frequencies) cochlear regions.
Discussion
These experiments demonstrated that adenovirus-based vectors can efficiently transduce cochlear hair cells in vivo, and that ototoxicity associated with the use of early generation (E1 The present study also demonstrated that cochlear function is a sensitive measure of virus toxicity when virus is directly infused into scala tympani. Exogenous DNA can be efficiently delivered and expressed for up to 8 days in adult cochlear hair cells using (E1
adenovirus vectors encoding genes important for cochlear function. Longer-term studies are currently underway to ascertain how long this class of vector persists in guinea pig cochleae. Since many genes have developmental roles, adenovirus-mediated gene delivery to adult animals will facilitate experiments on gene function independent of developmental consequences. Finally, the modified adenovirus perfusion technique allows expression of a gene specifically in the cochlea, without expression in other parts of the brain, a problem that can limit the usefulness of current transgenic technologies.
Previous in vitro experiments using replicationdeficient adenovirus vectors encoding either the CMV promoter driving the LacZ transgene, or the CMV promoter driving the green fluorescent protein transgene, also exhibited robust transgene expression when adenovirus vectors were used to transduce cultured hair cells. 3, 5 In contrast, previous in vivo studies using adenovirus-mediated gene transfer to hair cells encoding the RSV promoter driving expression of the LacZ gene failed to demonstrate efficient transduction of cochlear hair cells, 10, 15 which is in contrast to this report. There are a number of explanations that may account for the divergent results in this study to the previous in vivo adenovirus gene-transfer experiments. Aside from the differences in promoters used, previous adenovirus transduction attempts utilized titers of adenovirus (10 7 /cochlea) that were at least 10-fold lower than the amounts utilized the current study. Furthermore, unpublished studies in our laboratory have confirmed that attempts of virus infection at lower titers fail to transduce cochlear hair cells in vivo. Moreover, when cochlear function was monitored using auditory brainstem responses with low titer adenovirus infection, there was also no loss of these evoked potentials, which is an indirect indication that the hair cells were not transduced. 16 This outcome was in contrast to the loss of cochlear function observed by measuring DPOAEs in the current study using higher titers of (E1 − , E3 − ) adenovirus vectors that were slowly perfused into the cochlea.
Finally, differences in vector delivery also may have contributed to the different outcomes between the present results and those of previous reports. For example, earlier studies used a 3-min infusion of adenovirus into scala tympani, in contrast to the slow infusion (1 l/h) of adenovirus into the scala tympani that was used here. Using this slow-infusion approach, the virus remained in the catheter for approximately 50 h at 37°C, yet there was no significant loss of titer (Ͻ10%) from the initial titer to the titer after 50 h at 37°C. It has been demonstrated that adenovirus transduction of cells can be greatly enhanced by increasing contact time of the virus with the cell, 17 which could have also contributed to the transduction of the sensory hair cells in the current study.
Previous in vivo gene-transfer studies did report transgene expression in spiral ganglion cells and cells of the cochlear aqueduct in the contralateral ear, an observation not noted in the present study. 18 Possibly the slowinfusion method used here did not approach the pressure gradients associated with bolus infusions which reduces the driving force for virus to reach the cochlear aqueduct, and could account for the observed differences. A benefit of the perfused ear showing transgene expression with undetectable expression found in the contralateral ear is that this approach allows for intra-animal comparisons for controls. In addition, no transgene expression was detected in the brains of these animals which further confirms that the technique described here targets virus only to the perfused cochlea.
In summary, somatic gene transfer and expression of various genes into the guinea pig cochlear hair cells over extended time periods can now be envisioned. The welldescribed characteristics of this animal model for studies of normal and abnormal hearing 19, 21 will facilitate experimental designs aimed at evaluating both the causes of hearing loss and the potential to treat human deafness.
Materials and methods

Subjects
The study was performed on 10 adult pigmented guinea pigs (Ncr/2 strain) weighing 300-350 g and purchased from the Charles River Laboratories (Boston, MA, USA). The experimental design consisted of a pre/post-infusion comparison, with DPOAEs measured before and following perfusion of the adenoviral vectors into the cochlea using commercially available osmotic pump assemblies that were chronically implanted as described below. Additionally, the contralateral cochlea was examined both functionally, with DPOAEs, and immunohistochemically, for ␤-galactosidase expression (␤-gal), to ensure that the perfusion was specific to the pump-implanted cochlea.
Cochlear function assessment using DPOAEs Before DPOAE testing, the animals were sedated by an intramuscular (i.m.) injection of 40 mg/kg of ketamine hydrochloride and 1 mg/kg of acepromazine. DPOAEs at 2f 1 -f 2 were elicited and measured, conventionally, using equilevel (L 1 = L 2 ) primary tones produced by ER-2 speakers and an ER-10B
+ microphone assembly (Etymotic Research, Elkgrove, IL, USA). Stimulus generation and response acquisition were computer-controlled using an on-board digital signal processor, along with customized software controlling stimulus presentation and response analysis. 22 DPOAEs were obtained in the form of level/frequency functions, or DP-grams (see example in ) expressing cell line (C-7) that transcomplements the growth of the polymerase-deleted adenovirus vectors. 25 Both adenovirus vectors were then amplified in their respective cell lines, and confirmed to have the correct construction by restriction enzyme mapping of the vector genomes. Two CsCl purifications were performed to generate high titer vector preparations, followed by a ␤-gal assay using limiting dilutions, to determine the titers of both viruses in ␤-gal forming units (b.f.u.).
Osmotic-pump surgery
The implant surgery, performed under aseptic conditions, secured the osmotic pump (model 2001 (1 l/h), Alza Co, Palo Alto, CA, USA) in the middle ear. Specifically, the animals were anesthetized using an intramuscular injection of 40 mg/kg ketamine hydrochloride and 5 mg/kg of xylazine. A skin incision was made initially Gene Therapy at the midline to expose the dorsal surface of the skull. Using a dental burr, a 1.5-mm hole was drilled through the calvarium at a vertex site 1 cm posterior to the bregma suture, and a self-tapping stainless-steel screw was introduced to anchor the pump's cannula to the skull. The cannula was fashioned according to the specifications detailed elsewhere, 26 and included a drop of silicon at its distal terminus in the cochlear base.
Another incision extending along the dorsal skin to a post-auricular locus, allowed the exposure of the bullar portion of the temporal bone. A small defect was created in the bulla using the tip of a scalpel blade and widened sufficiently to visualize the round window, as shown in Figure 1a . The cannula of the pump was filled with the infusion substance and clamped at the pump end. Using a fine sharpened metal probe, a small hole was created through the cochlear bone at its base, and the tip of the cannula was inserted until the silicon drop was seated securely against the bone, thus, extending the cannula about 0.5 mm into scala tympani. A drop of cyanoacrylate cement was applied at the bulla defect to anchor the cannula at this site. Following confirmation of cannula placement, the remainder of the defect was covered with carboxylate cement. To accommodate the body of the osmotic pump, a subcutaneous pocket was then made between the scapulae. Before seating the pump, its flow moderator was inserted into the cannula. To secure the cannula, its middle portion was looped around the vertex screw, cemented with methyl methacrylate to the skull and the skin incision closed.
Cochlear perfusions
In all experiments, artificial perilymph (145 mm NaCl, 2.7 mm KCl, 2 mm MgSO 4 , 1.2 mm CaCl 2 , 5 mm HEPES buffer) was used as the carrier solution. Three guinea pigs received control cochlear perfusions with artificial perilymph only. The respective adenovirus vectors were perfused into six guinea pig cochleae using 5 × 10 8 b.f.u. of the virus per cochlea. All aspects of this experiment were reviewed and approved by the University of Miami's Institutional Animal Care and Use Committee.
␤-Galactosidase immunohistochemistry
After perfusion, the presence of the transgene was detected using immunohistochemistry for the ␤-gal protein. Immunohistochemistry was used rather than the enzyme histochemistry, since endogenous ␤-gal activity present in the guinea pig cochlea (A Luebke, unpublished observation) prevented detection of ␤-gal activity derived from the vector genome. In addition, enzyme histochemistry to detect LacZ gene expression has been shown to underestimate the transfection efficiency. 25 Toward this end, the animals were terminated with an overdose of pentobarbital, and perfused with 4% paraformaldehyde. Both cochleae were then harvested and decalcified in 0.1 m EDTA. Following decalcification, the cochlear halfturns were microdissected and processed to detect the presence of the ␤-gal using an anti-␤-gal antibody (Promega, Madison, WI, USA). Cochlear half-turns were incubated overnight in the ␤-gal antibody (1:1000) in 0.01 m PBS at room temperature. After washing with PBS, the tissues were incubated for 1 h with a donkey-anti-rabbit secondary antibody (1:800) conjugated to biotin (Jackson Immunoresearch Laboratories, West Grove, PA, USA), and then washed and incubated in ABC reagent for 1 h (Vector Laboratories, Burlingame, CA, USA), according to the manufacturer's specifications. Finally, the tissues were incubated in diaminobenzidine, cleared in glycerol, and mounted on depression slides for light-microscopy viewing. To obtain cross-sections of these whole mounts, the sections were embedded in plastic (araldite) and cut into thick sections following the methodology described by Bohne. 28 
